IOL

Patient selection is important.

David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.

GreenMan app provides patients an opportunity to test drive various IOL options before cataract surgery via virtual and augmented reality.

A tailored treatment plan can help surgeons offer personalized care for patients.

Mariam Maghribi, Chief Business Officer for Shifamed, spoke with Ophthalmology Times about the Atia Vision IOL device at this year's American Academy of Ophthalmology meeting.

Daniel Chang, MD, spoke with Ophthalmology Times about his poster "Clinical performance of a diffractive, extended depth-of-focus IOL, with violet light filtering and high-resolution lathing" at this year's American Academy of Ophthalmology meeting.

Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America spoke with Ophthalmology Times about 3 new technologies the company launched at this year's American Academy of Ophthalmology meeting.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.

The study monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL).

Surgeons can refine their workflow, partner with an optometrist.

Lens is stable in capsular bag, less sensitive to misalignment.

Surgeons seek best IOL match for patients after cataract surgery.

Eyes implanted with the lens demonstrated greater astigmatic tolerance.

Sam Garg, MD, discussed his paper on the 36-month outcomes for the Juvene modular intraocular lens at the 2023 ASCRS annual meeting in San Diego.

Daniel Chang, MD, discussed his paper on a study comparing TECNIS Symfony OptiBlue IOL with the TECNIS Symfony Legacy IOL at the 2023 ASCRS annual meeting in San Diego.

Rob Thornhill, CEO of Centricity Vision, discussed the FDA clearing of ZeptoLink at the 2023 ASCRS annual meeting in San Diego.

Ophthalmology Times© met with Eva Liang at the 2023 ASCRS annual meeting in San Diego where she presented data on outcomes of the Rasch-scaled Catquest-9SF questionnaire before and after implantation of the enVista toric lens.

Ophthalmology Times© caught up with Alice Epitropoulos at the 2023 ASCRS annual meeting in San Diego. Among her presentations at the event, she shared data regarding the visual and refractive outcomes of aberration-free monofocal hydrophobic toric IOLs.

Alcon presented details from a new study at the American Society of Cataract and Refractive Surgery’s annual meeting taking place in San Diego, California. The investigator-initiated study led by J. Morgan Micheletti, MD, demonstrated that Clareon and Eyhance monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.

George Waring IV, MD met with the onsite Ophthalmology Times© team to share data from his presentation on the first in-human results for the OmniVu IOL system.

Ophthalmology Times© met with Robert Lin, MD at the 2023 ASCRS meeting in San Diego, where he shared his experience using ICLs in his practice and the advancements that help make these devices the right choice for patients.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Erisa Yotsukura, MD, PhD, offered details of a study examining an IOL that transmits violet light and a second option that does not, and they believe this can affect differences in the choroidal thickness after cataract surgery.

According to the company, outcomes show the potential for its modular, shape changing lens system.

The company’s CT Lucia 621P monofocal IOL enables surgeons to treat a wide range of cataract patients while supporting optimized visual outcomes.